ViiV claims $1.25bn settlement from Gilead in HIV patent dis...

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV pr

Novartis blocks generic to MS blockbuster Gilenya in US pate...

Novartis has blocked an attempt by Chinese drugmaker HEC Pharma to launch a generic version of its big-selling multiple sclerosis drug Gilenya in the US for almost six years.

Gilead will challenge US government patent on PrEP drug Truv...

Novartis secures initial block on Gilenya generics in US

EU Pharmaceutical Law Forum

DIG DEEPER INTO CUTTING EDGE TOPICS

SMi’s release speaker interview Anita Burrell, speaker at Bi...

Biosimilars USA conference information